Research Article Details
| Article ID: | A08749 |
| PMID: | 32001430 |
| Source: | Wiad Lek |
| Title: | Correction of adipocyte secretion disorders in patients with non-alcoholic fatty liver disease with overweight and obesity |
| Abstract: | Introduction: The attention of scientists from many countries is focused on hormonal substances - adipokines at the present time. Lowering the level of the hormone adiponectin plays a central role in the development of obesity and cardiovascular disease in humans. The aim of the work is to determine the effect of complex therapy of thiotriazolin and L-lysine escinate on adipocyte secretion indices in patients with non-alcoholic fatty liver disease (NAFLD) with overweight and obesity. Material and Methods: 135 patients with overweight and obesity were examined, 46 of which were overweight (BMI-25-29.9 kg / m2), 34 were obesity grade I (BMI-30-34.9 kg / m2), 20 - Obesity II degree (BMI-35-39.9 kg / m2). 35 patients had normal body mass (BMI 18-24.9 kg / m2). We also examined 20 practically healthy persons. The age of the examinees varied, the median age was 55 years (intercourt scale Q1-Q3 from 40 to 61 years). The verification of the diagnosis of NAFLD was conducted in accordance with the recommendations of the Unified Clinical Protocol. Results: The additional use of thiotriazolin and L-lysine escinate significantly influenced the adiponectin concentration level. Compared with the period before treatment, the adiponectin level increased in patients with overweight and obesity in 1,6 times (p <0.05). Compared to baseline, the adiponectin content in patients with NAFLD increased by 24.6-27.6% (p <0.05). Also, the level of leptin decreases significantly in patients with overweight and obesity (p <0.05). Conclusions: Integrated therapy with thiotriazolin and L-lysine escinate is an effective way to normalize the level of adipokines in patients with NAFLD with overweight and obesity. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |